Slough's new chief executive, Ian Coull, has asked UBS to drawup a range of options for unlocking the value in its Americanassets. These include a sale, wholesale demerger, retaining a stakein a new company or a tax-efficient property investment trust.

The aim is to streamline Slough into a specialist developmentcompany better equipped to generate improved returns on capitalthan it can from pure property investment.

Slough has built a profitable business in the southernCalifornia property market with the development of thebiotechnology parks. They have attracted tenants like Pfizer whichnow occupies 25% of the property in the portfolio and this hasboosted the investment value of the estate.

Want to continue reading?
Become a Free ALM Digital Reader.

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.